^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ACTR707

i
Other names: ACTR707, ACTR 707
Associations
Trials
Company:
Cogent Biosci
Drug class:
T-lymphocyte cell therapy
Associations
Trials
1year
Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B-Cell Lymphoma. (PubMed, Transplant Cell Ther)
The ATTCK-20-03 trial serves as proof of principle regarding the ACTR approach that could potentially be used with other antibodies targeting other markers in other malignancies. Although the ACTR707 program has been discontinued, these results may support other programs in employing similar novel approaches of antibody-coupled T-cell activation.
P1 data • Journal • Combination therapy • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • ACTR707
3years
ATTCK-20-03t: Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma (clinicaltrials.gov)
P1, N=26, Terminated, Cogent Biosciences, Inc. | Active, not recruiting --> Terminated; Business decision
Clinical • Trial termination • Combination therapy
|
CCND1 (Cyclin D1)
|
CCND1 expression
|
Rituxan (rituximab) • ACTR707
over4years
Clinical • P1 data • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
|
Herceptin (trastuzumab) • ACTR707
5years
Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma (ASH 2019)
ACTR707 is in clinical development in combination with rituximab (NCT03189836) or trastuzumab (NCT03680560)...Subjects receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) for 3 days, followed by rituximab and a single dose of ACTR707... Data available from DL1 through DL3 of ACTR707+rituximab suggest that clinical responses can be achieved without severe T cell-mediated toxicities (eg, CRS and neurotoxicity) that have been reported with other autologous T-cell products. Dose escalation continues at a target dose of 80×106 ACTR+ T cells; enrollment in DL4 (n=6) was recently completed. Updated data, including identified correlates of clinical outcomes, will be presented for DL1 through DL4.
Clinical • P1 data • Combination therapy
|
CD8 (cluster of differentiation 8)
|
Herceptin (trastuzumab) • Rituxan (rituximab) • fludarabine IV • ACTR707